Effect of Yiqi Buxue Decoction on Hemodynamic Changes of the Uterine Artery and Fetal Umbilical Artery and Pregnancy Outcomes in Pregnant Patients with Pulmonary Arterial Hypertension.

Rendong Han,Liya Gao,Chunxia Deng,Mei Li,Hongbo Sun

doi:10.1155/2021/1849114

Abstract

Objective To explore the effect of Yiqi Buxue decoction on hemodynamic changes of the uterine artery and fetal umbilical artery and pregnancy outcomes in pregnant patients with pulmonary arterial hypertension (PAH). Methods 120 pregnant patients with PAH treated in our hospital (January 2019-January 2020) were chosen as the research objects, and randomly split into group A (n = 60) and group B (n = 60). Both groups received routine treatment, and group B was treated with sildenafil citrate, while group A was treated with Yiqi Buxue decoction combined with sildenafil citrate. Both groups received 6 weeks of treatment to analyze the hemodynamic changes of the uterine artery and fetal umbilical artery and compare the cardiopulmonary function indexes and pregnancy outcomes between the two groups. Results The hemodynamic indexes of the uterine artery and fetal umbilical artery, cardiopulmonary function indexes, and pregnancy outcomes in group A after treatment were notably better compared with group B (P < 0.01). Conclusion Yiqi Buxue decoction can stabilize the hemodynamics of pregnant patients with PAH, improve their cardiopulmonary function, alleviate hypotension, and thus, reduce the possibility of adverse pregnancy outcomes, which should be popularized in practice.

Highlights

Pulmonary hypertension (PAH) during pregnancy refers to structural and functional changes in the pulmonary vessels caused by nonspecific causes, which is mainly characterized by elevated pulmonary vascular resistance (PVR)
Western medicine treatment is often adopted to improve the hemodynamics of patients in practice, and targeted PAH drugs are gradually introduced, including anticoagulant drugs such as sildenafil citrate to alleviate the hypercoagulable state of patients and enhance their cardiopulmonary function
Occurring mostly in women of childbearing age, PAH will cause intimal hyperplasia of the pulmonary arteries, autochthonous thrombus, and increased pulmonary vascular resistance, increasing the right heart load of patients and leading to heart failure or death in severe cases. Both secondary PAH and primary PAH are absolute contraindications of pregnancy because patients in pregnancy will undergo a series of physiological changes that will greatly increase the mortality and the incidence of adverse pregnancy outcomes [6, 12,13,14]

Summary

Introduction

Pulmonary hypertension (PAH) during pregnancy refers to structural and functional changes in the pulmonary vessels caused by nonspecific causes, which is mainly characterized by elevated pulmonary vascular resistance (PVR). With obvious hemodynamic abnormalities and significantly increased cardiac load, patients are prone to heart failure under the influence of physiological changes during pregnancy, which seriously threatens maternal and child health [1,2,3]. Studies have shown that PAH is one of the leading important causes of perinatal death in patients, accounting for 12% of all causes of maternal death. For patients with Eisenmenger syndrome, the mortality rate remains about 25% [5, 6], suggesting a high possibility of adverse pregnancy outcomes. Western medicine treatment is often adopted to improve the hemodynamics of patients in practice, and targeted PAH drugs are gradually introduced, including anticoagulant drugs such as sildenafil citrate to alleviate the hypercoagulable state of patients and enhance their cardiopulmonary function. Yiqi Buxue decoction is a common drug to regulate qi and blood in clinic, which is able to improve the obstructed blood flow of patients, reduce

Methods

Results

Conclusion